Myriad RBM Announces the Launch of OncologyMAP® v. 2.0

Myriad RBM Announces the Launch of OncologyMAP® v. 2.0

Myriad Genetics (NASDAQ: MYGN) announced today that Myriad RBM, a wholly owned subsidiary of Myriad Genetics, has launched OncologyMAP® v. 2.0, a powerful research tool developed with funding and direction from the National Cancer Institute and the Cancer Prevention Research Institute of Texas. OncologyMAP® v. 2.0 is a comprehensive, cost-effective testing service that builds on the success of the original OncologyMAP® service by increasing the scope and diversity of biomarker analysis for drug re-tasking, indication expansion, and patient stratification studies and provides researchers with the ability to accelerate the pace of discovery, validation, and translation of cancer biomarkers into clinically useful tests......................

paywalled: US firm corners exclusive license for RAD51C cancer gene : The Lancet Oncology (breast/ovarian mutation)

US firm corners exclusive license for RAD51C cancer gene : The Lancet Oncology

US firm corners exclusive license for RAD51C cancer gene

Bryant Furlow

 

"Already facing a legal challenge to its BRCA1 and BRCA2 patents, Myriad Genetics (Salt Lake City, UT, USA) has secured an exclusive licence for another breast and ovarian cancer-associated gene, RAD51C , under agreement with the German Consortium for Hereditary Breast and Ovarian Cancers, which will share exclusivity in Germany. RAD51C will be used to test patients' hereditary breast and ovarian cancer risks.

“I think it is unfortunate for both the clinical and research communities”, Jim Evans (University"

media: AMP Optimistic in Suit to invalidate Patents on Breast Cancer Genes (BRCA/ovarian....)

Blogger's Note: typical reminder that the Myriad 'breast cancer' genetic testing is not only for breast cancer

AMP Optimistic in Suit to invalidate Patents on Breast Cancer Genes

Reuters: Myriad gene patent ruling sent back to lower court

 Reuters: Myriad gene patent ruling sent back to lower court

"The move is expected to delay a verdict in the Myriad case by as much as several years."

Myriad Genetics slips on patent concerns - BusinessWeek

Myriad Genetics slips on patent concerns - BusinessWeek

Myriad Genetics Announces the Release of Support360.com - DigitalJournal.com (press release)

Myriad Genetics Announces the Release of Support360.com - DigitalJournal.com (press release):

Myriad Genetics Announces the Release of Support360.com DigitalJournal.com (press release) The site is a unique, personalized resource for information and encouragement about risk testing for hereditary forms of breast, ovarian and other types of cancers, including Hereditary Breast and Ovarian Cancer Syndrome and Lynch Syndrome. and more »

Myriad, Prometheus Continue to Defend Diagnostic Patents while Others Urge More Licensing (BRCA patients)

[Lancet Oncology News] US firm corners exclusive license for RAD51C cancer gene

[News] US firm corners exclusive license for RAD51C cancer gene:

"Already facing a legal challenge to its BRCA1 and BRCA2 patents, Myriad Genetics (Salt Lake City, UT, USA) has secured an exclusive licence for another breast and ovarian cancer-associated gene, RAD51C, under agreement with the German Consortium for Hereditary Breast and Ovarian Cancers, which will share exclusivity in Germany. RAD51C will be used to test patients' hereditary breast and ovarian cancer risks."

Myriad Genetics’ Australian Cancer Gene Patents Go on Trial in Sydney, Australia - Bloomberg

Patents on Genetic Data Raise Legal Questions on Rights to DNA - Bloomberg

US firm (Myriad) corners exclusive license for RAD51C (breast/ovarian)cancer gene : The Lancet Oncology

 abstract

Bryant Furlow

"Already facing a legal challenge to its BRCA1 and BRCA2 patents, Myriad Genetics (Salt Lake City, UT, USA) has secured an exclusive licence for another breast and ovarian cancer-associated gene, RAD51C , under agreement with the German Consortium for Hereditary Breast and Ovarian Cancers, which will share exclusivity in Germany. RAD51C will be used to test patients' hereditary breast and ovarian cancer risks.

“I think it is unfortunate for both the clinical and research communities”, Jim Evans (University ..."

To read this article in full you will need to make a payment

open access: BMC Cancer - Predictive models for mutations in mismatch repair genes: implication for genetic counseling in developing countries (Lynch Syndrome)

 Background

Lynch syndrome (LS) is the most common form of inherited predisposition to colorectal cancer (CRC), accounting for 2–5% of all CRC. LS is an autosomal dominant disease characterized by mutations in the mismatch repair genes mutL homolog 1 (MLH1), mutS
homolog 2 (MSH2), postmeiotic segregation increased 1 (PMS1), post-meiotic segregation increased 2 (PMS2) and mutS homolog 6 (MSH6). Mutation risk prediction models can be incorporated into clinical practice, facilitating the decision-making process and identifying
individuals for molecular investigation. This is extremely important in countries with limited economic resources. This study aims to evaluate sensitivity and specificity of five predictive models for germline mutations in repair genes in a sample of individuals with suspected
Lynch syndrome.

"Lynch syndrome (LS) is the most common form of inherited predisposition to colorectal cancer (CRC), accounting for 2–5% of all CRC [1]. Colorectal cancer in LS differs from sporadic cases by an earlier age of diagnosis (mean age approximately 44 years), a predominance of proximally-sited colon cancers (60–70%) and an increased propensity to
synchronous or metachronous CRCs (25%) [2,3]. Individuals with LS have an 80% probability of developing CRC at 65 years, and they are at an elevated risk of developing a second primary CRC [4] as well as at an increased risk for extra-colonic malignancies, including endometrial, gastric, small bowel, urological tract, ovary, pancreas and brain cancer
[5]."

 Conclusions

The Barnetson, PREMM, MMRpro and Wijnen models present similar AUC. The AUC of the Myriad model is statistically inferior to the four other models. 

The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.

Myriad Cert Petition Now Fully Briefed; Supreme Court May Decide by Feb. 20 | Bloomberg BNA

Jan 2012 BRCA patent dispute may head to US Supreme Court : The Lancet

"The long-running dispute over patents for the BRCA1 and BRCA2 genes granted to Myriad Genetics may finally be laid to rest by the US Supreme Court....."

Myriad Genetics Gets (Worldwide) Rights To RAD51C Gene

"...Through this agreement, Myriad has obtained an exclusive, world-wide license, with co-exclusivity in Germany, to provide commercial testing for RAD51C."

Gene Patent (Myriad) in Cancer Test Upheld by Appeals Panel - NYTimes.com (BRCA 1/2)

Editorial - Human gene patents limit access to care :: March 7, 2011 ... American Medical News

Genetics Company Myriad May Shift From Patents To Proprietary Data | Intellectual Property Watch

How Will Myriad Respond to the Next Generation of BRCA Testing? GenOmics

A Do-It-Yourself Genomic Challenge to Myriad, the FDA and the Future of Genetic Tests (long)